Time: 10 AM EST | November 24, 2025

CAR-T therapy has achieved remarkable success in hematologic malignancies but faces major hurdles in solid tumors due to their immunosuppressive microenvironment. Angiogenesis, driven by the VEGF pathway, plays a critical role in fueling tumor growth and suppressing immune responses.

We are honored to host Dr. Mark Leick, who will present an innovative approach using CAR-T cells engineered to deliver anti-VEGF therapeutics (CARVEGF). These “Trojan horse” CAR-T cells not only kill tumor cells but also locally block VEGF signaling to disrupt angiogenesis and enhance T-cell function.

Key topics include:

• Activation of the VEGF pathway in CAR-T cells
• Enhanced in vitro anti-tumor activity and proliferation of CARVEGF
• Potent in vivo efficacy in ovarian, lung, and RCC solid tumor models

Join us to explore how CARVEGF offers a dual mechanism to overcome the barriers of solid tumor therapy.